医生应该谈论与患者的安慰剂效果吗？

临床和实验室研究表明，安慰剂和NOCEBO效应影响惰性和活性治疗后的各种症状和条件。关于如何通知患者在临床实践和培训临床医生如何透露这些信息的情况下向患者通知患者的最新建议，越来越需要。

根据先前关于安慰剂和诺克斯效应的临床建议，通过开放和封闭式的调查问题进行了一项研究，然后是最终的专家会议组成。调查被细分为3部分：（1）通知耐心关于安慰剂效应，（2）通知患者关于NOCEBO效应，（3）培训临床医生如何向患者传达这些信息。

The results of the surveys showed that there was consensus on communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities.

目前的研究提供了基于共识的建议和披露的实际考虑因素安慰剂和nocebo效应临床实践。如何在如何最佳地定制信息以及特定的临床条件和患者需求，以及为临床医生开发标准化披露培训模块的未来研究。

---

---